ArticleThe Journal of biological chemistry2017
G
Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- C-type lectin-like receptor 2: roles and drug target.Thrombosis journal · 2024Review
- Review
- Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin.Biomedicines · 2023Review
- Factors Associated with Platelet Activation-Recent Pharmaceutical Approaches.International journal of molecular sciences · 2022Review
- A Comparative Assessment Study of Known Small-molecule GPVI Modulators.ACS medicinal chemistry letters · 2022Article
- Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath.Expert opinion on therapeutic targets · 2022Review
- Macrocyclic Gq Protein Inhibitors FR900359 and/or YM-254890-Fit for Translation?ACS pharmacology & translational science · 2021Article
- Diverse innate stimuli activate basophils through pathways involving Syk and IκB kinases.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Platelets in HIV: A Guardian of Host Defence or Transient Reservoir of the Virus?Frontiers in immunology · 2021Review
- SARS-CoV-2 vaccination induced cerebral venous sinus thrombosis: Do megakaryocytes, platelets and lipid mediators make up the orchestra?Free neuropathology · 2021Article
- Monocyte upregulation of podoplanin during early sepsis induces complement inhibitor release to protect liver function.JCI insight · 2020Article
- Control of Platelet CLEC-2-Mediated Activation by Receptor Clustering and Tyrosine Kinase Signaling.Biophysical journal · 2020Article
- Heterotrimeric GThe Journal of biological chemistry · 2020Review
- TULA-2 Deficiency Enhances Platelet Functional Responses to CLEC-2 Agonists.TH open : companion journal to thrombosis and haemostasis · 2018Article
- Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases.Pharmacological reviews · 2018Review
- Src family kinase tyrosine phosphorylates Toll-like receptor 4 to dissociate MyD88 and Mal/Tirap, suppressing LPS-induced inflammatory responses.Biochemical pharmacology · 2018Article
- An experimental strategy to probe Gq contribution to signal transduction in living cells.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Platelets play a key role in the physiological hemostasis or pathological process of thrombosis. Rhodocytin, an agonist of the C-type lectin-like receptor-2 (CLEC-2), elicits powerful platelet activation signals in conjunction with Src family kinases (SFKs), spleen tyrosine kinase (Syk), and phospholipase γ2 (PLCγ2). Previous reports have shown that rhodocytin-induced platelet aggregation depends on secondary mediators such as thromboxane A2 (TxA2) and ADP, which are agonists for G-protein-coupled receptors (GPCRs) on platelets. How the secondary mediators regulate CLEC-2-mediated platelet activation in terms of signaling is not clearly defined. In this study, we report that CLEC-2-induced Syk and PLCγ2 phosphorylation is potentiated by TxA2 and that TxA2 plays a critical role in the most proximal event of CLEC-2 signaling,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.